1. Introduction {#s0010}
===============

Monepantel (trade name Zolvix®) was launched, firstly in New Zealand in 2009, and then in Australia and the UK in 2010 by Novartis Animal Health. It was the first new drug family of anthelmintic to appear on the livestock healthcare market for over 25 years ([@bib0165]). In an effort to prolong the useful life of this new compound and protect the efficacy of the older anthelmintic families, monepantel has been sold as prescription only medicine (POM-V) in the UK. Although efforts have been made to "protect" the compound, the first cases of resistance have been reported only two years after its launch. The first case of resistance was reported in sheep and goats in New Zealand ([@bib0195; @bib0310]) and another case was reported on a goat farm in New South Wales, Australia (<https://wormmailinthecloud.wordpress.com/?s=monepantel+resistance>; last accessed 30APR15). All reports have found that *Teladorsagia circumcincta* was one of the parasites surviving treatment.

An understanding of the development of anthelmintic resistance and evolvement of parasites in the face of anthelmintic pressure is key to developing strategies to preserve their efficacy. Previously different selection processes for the assessment of anthelmintic resistance have been used: (a) comparison of anthelmintic resistant and sensitive field derived isolates ([@bib0190; @bib0145; @bib0180; @bib0155; @bib0160]); (b) experimental selection via increasing sub-therapeutic dosages *in vivo* ([@bib0175; @bib0090; @bib0120; @bib0140; @bib0315; @bib0290; @bib0280; @bib0085]); (c) *in vitro* pressurisation and selection of individuals within a population with an inherent insensitivity to a compound and use them for *in vivo* trials ([@bib0215; @bib0165]); (d) comparison of populations pre- and post-*in vitro* anthelmintic exposure ([@bib0185; @bib0100]); (e) introgression of resistant genes into sensitive populations through the process of backcrossing individuals ([@bib0285]); (f) comparison of clade V free living model nematode systems to extrapolate information on parasitic nematodes ([@bib0105; @bib0070]).

Phenotypic variation in life history traits following selection for benzimidazole (BZ; [@bib0145; @bib0150; @bib0180; @bib0215; @bib0200]) and ivermectin (IV; [@bib0110; @bib0115]) resistance has been examined previously in a number of parasite species. Historically, it was believed that chemotherapy that impacts on adult parasite life expectancy would result in one of the two outcomes: either earlier development to sexual maturity of parasites in order to propagate prior to treatment, or delayed development to avoid the effects of treatment ([@bib0015; @bib0320]). The finding from the aforementioned selection studies would suggest that the impact of the development of resistance on phenotypes, as one might expect, is not so clear cut, and it is influenced by a number of host related/physiological (e.g. age, size, diet, immune status, presence of conspecifics and heterospecifics) and environmental factors ([@bib0260]).

The aims of this study were: firstly, to generate *T. circumcincta* isolates selected for monepantel resistance from previously phenotypically characterised parental isolates to improve our understanding of the development, dissemination and detection of MPTL resistance and secondly, to assess the extent of phenotypic changes that occur in selected isolates compared to parental isolates following selection for resistance to MPTL.

2. Materials and methods {#s0015}
========================

2.1. Parasite isolates {#s0020}
----------------------

Three *T. circumcincta* (designated MTci2, MTci5 and MTci7) isolates were used to generate the MPTL resistant isolates, as outlined in [section 2.2](#s0025){ref-type="sec"} ([Table 1](#t0010){ref-type="table"}). MTci2 is phenotypically sensitive to all broad spectrum anthelmintics (unpublished data) whilst MTci5 and MTci7 are phenotypically BZ, levamisole (LV) and IV resistant ([@bib0295; @bib0020; @bib0025]). MTci7 also exhibits moxidectin (MX) resistance ([@bib0300; @bib0350]). The isolates were passaged through parasite naive lambs that were housed under conditions that precluded contamination with other nematode species prior to use. During the period of selection, the parental isolates were independently passaged four times.

2.2. Monepantel resistance selection process {#s0025}
--------------------------------------------

Three MPTL resistant *T. circumcincta* isolates were artificially selected *in vivo* from phenotypically characterised isolates using an adaptation of a previously outlined methodology ([@bib0085]). In brief, lambs were initially mono-specifically infected with approximately 20,000 infective larvae of MTci2, MTci5 or MTci7. Due to availability of stocks, the infective larvae used to initiate the infections were 1, 4 and 11 months old for MTci7, MTci2 and MTci5, respectively. All subsequent infections were less than 1 month old when administered. All larvae were assessed visually to ensure they appeared active. Prior to infection all larvae were stored in 100 ml tap water in 75 cm^2^ suspension culture flasks (Startsedt Ltd, Germany) between 4 and 8 °C. At patency, lambs were administered monepantel (Zolvix®, Novartis Animal Heath) at 0.125 mg/kg bodyweight (BW), 1/20th of the manufacturer\'s recommended dose rate. The lowest dose used was selected because previous work had demonstrated that even a dose of 1.25 mg/kg BW had been effective at removing \>99% of *T. circumcincta* populations ([@bib0170]). Eggs from surviving worms were collected and cultured to generate infective larvae. Lambs with positive faecal egg counts (FEC) were re-treated at increasing dose rates of MPTL (e.g. 0.25, 0.5, 0.63, 0.83, 1.25, 1.88 and 2.5 mg/kg BW) until egg counts dropped. At this point, the larvae obtained from the highest dosage were either used to re-infect the donor that had been previously treated or used to infect a new donor. At patency, the process was repeated using increasing dose rates until a fully resistant isolate, i.e. able to survive a full therapeutic dose rate (2.5 mg/kg BW), was generated. Further information can be found in the supplementary material file attached.

2.3. Monepantel efficacy trial design {#s0030}
-------------------------------------

The monepantel efficacy trial overall included 10 groups including parent (without anthelmintic treatment) and selected (with and without monepantel administration on day 28, i.e. -CON and -MPTL) isolates. Five lambs were randomly allocated to each of the 10 groups: MTci2, MTci5, MTci7, MTci7-MPTL, MTci2-11-CON, MTci5-13-CON, MTci7-12-CON, MTci2-11-MTPL, MTci5-13-MTPL, MTci7-12-MTPL ([Table 1](#t0010){ref-type="table"}). The group MTci7-MPTL is a treatment validation group, included for those infected with the parental isolate MTci7, to confirm that MPTL was effective at removing adult populations in the original parental isolate. On day 0, Suffolk greyface worm-free crossbred lambs of 5 to 9 months were challenged *per os* with 7000 infective larvae from one of the three parental isolates (MTci2, MTci5 or MTci7) or three monepantel selected isolates (MTci2-11, MTci5-13 or MTci7-12) according to the constituent of group. Faecal egg counts were conducted on the lambs prior to the start of the trial to confirm their worm-free status, and on the day of treatment (day 28) to allow the formation of groups within which all lambs have similar egg counts. Further FECs were conducted throughout the trial to assess time to patency and magnitude of egg output (details in [section 2.3.1](#s0035){ref-type="sec"}). On day 28 post-infection, the lambs were weighed and dosed orally by syringe at the manufacturer\'s recommended dose rate with either Zolvix® (2.5 mg/kg BW; -MPTL) or left untreated to act as controls (-CON). All anthelmintic administrations were rounded up to the nearest 0.2 ml (dosage range 2.5--2.7 mg/kg BW). All of the animals were necropsied seven days post-treatment; the methods used to euthanase the animals, remove and process their organs for worm burden recovery were as described by [@bib9015]. The total worm burdens were estimated from 2% sub-samples of the abomasal washings and saline digests. Recovered worms were sexed and staged ([@bib9010]).

Due to animal, material and time constraints the above trials were conducted at two separate time points. The controlled efficacy test (CET) using MTci7 and its selected isolate (MTci7-12) was investigated in one trial whilst MTci2, MTci5, MTci2-11 and MTci5-13 were investigated in a second trial. All experimental procedures described here were approved by the Moredun Research Institute Experiments and Ethics Committee and were conducted under the legislation of a UK Home Office License (reference PPL 60/03899) in accordance with the Animals (Scientific Procedures) Act of 1986.

### 2.3.1. Faecal egg counts {#s0035}

Faecal samples were taken *per rectum* from each lamb prior to infection to confirm that they were negative for nematode eggs: from day 8 post infection (PI) egg counts, eggs per gram (EPG), were performed three times a week to assess pre-patency of the isolates, on day 27 PI prior to the anthelmintic treatment (day 28), and then daily until necropsy seven days later. Faecal egg counts were conducted throughout the trials using a modification of a salt flotation method with a sensitivity of up to one egg per gram ([@bib0075]), allowing the evaluation of the effectiveness of the anthelmintic on faecal egg count reduction.

### 2.3.2. Eggs *in utero* and worm body lengths {#s0040}

Twenty individual adult worms (20 male and 20 female worms where available) were randomly selected from each lamb within a group, mounted in a drop of lactophenol (GCC Diagnostics) on a microscope slide and assessed for fecundity. The numbers of eggs *in utero* in female worms were enumerated at magnification (×40) on a compound microscope. Images were captured (Nikon D70) of each individual for length determination; where multiple images were captured, the images were compiled to form a single composite image using an image editing program (Adobe Photoshop Elements 4.0). Worm lengths were estimated using image processing software (ImageJ 1.46r).

2.4. Statistical analysis {#s0045}
-------------------------

The main effects to be investigated were: comparisons between groups corresponding to the parental isolates (MTci2, MTci5, MTci7), comparisons between groups corresponding to the parent and selected isolates (versus MTci2-11-CON, MTci5-13-CON, MTci7-12-CON), and finally, comparisons between groups corresponding to the selected isolates without treatment (-CON) and with treatment (-MPTL) (versus MTci2-11-MTPL, MTci5-13-MTPL, MTci7-12-MTPL).

### 2.4.1. Parasite establishment and worm burden {#s0050}

The data on each stage of worm burden (juvenile, male, female and total) in individual lamb were investigated by fitting a generalised linear mixed model (GLMM) to the counts using a logarithmic link function and assuming the Poisson distribution. Estimates of establishment rate (the proportion of juvenile and adult worms recovered from the initial challenge dose i.e. 7000) and development rate (the proportion of adult worms out of total worms established) were obtained for each group by fitting a GLMMs using a logit link function and assuming the binomial distribution. All models included group as a fixed effect, and lamb (the level of each observation) as a random effect to allow for over-dispersion.

### 2.4.2. Treatment efficacy {#s0055}

The percentage efficacy of the treatment for each selected isolate was calculated using the equation: (1-(T/C)) × 100, where C and T are the arithmetic mean total worm burdens or faecal egg counts at 35 days PI of the control (-CON) and treated (-MPTL) groups, respectively ([@bib0080]). According to [@bib0080], anthelmintic resistance was deemed to be present when the mean percentage efficacy at reducing faecal egg output or worm burden was less than 95%.

### 2.4.3. Adult worm body length {#s0060}

The data on length of male and female worms were each analysed using a linear mixed model (LMM). The model included group as a fixed effect and lamb as a random effect.

### 2.4.4. Per capita fecundity {#s0065}

The worm egg counts *in utero* were analysed using a GLMM with a logarithmic link function and assuming the Poisson distribution. The model incorporated the group as a fixed effect and lamb as a random effect, and worm as a random effect to allow for over-dispersion. Two separate GLMMs were investigated, with and without an offset variable of the logarithm of the female worm length. An additional GLMM was also fitted to estimate the effect of logarithm of the female worm length on the egg counts.

### 2.4.5. Time to patency {#s0070}

The data on time to patency for each animal were calculated as the time when the faecal egg count is greater than or equal to 25 eggs per gram. This was analysed using a linear model (LM). The model included the isolate, combining the two groups for each selected isolate (-CON and -MPTL), as a fixed effect, because days to patency are before the treatment day (i.e. day 28).

### 2.4.6. Daily and cumulative faecal egg count {#s0075}

To investigate the effect of group on the faecal egg counts of lambs, two different approaches were used. First, the logarithm of faecal egg counts (count+1) data for each lamb on each time point (day) until day 35 of the experimental period (including both pre and post-anthelmintic treatment phases) were analysed by an additive LMM. The model included group as a fixed effect and separate smoothing curves for each group to consider the non-linear relationship of faecal egg count with day. The model incorporated lamb as a random effect and heterogeneity in variance for each group. Model selection was based on the Akaike\'s information criterion (AIC). Secondly, to compare the overall faecal egg counts, the cumulative egg count for each lamb during the entire experimental period was estimated by calculating the area under the curve (AUC) of EPG using the trapezoid method. A linear model (LM) was fitted to the square root transformed AUC data for control lambs only, incorporating the group as a fixed effect.

### 2.4.7. General modelling strategy {#s0080}

If all lambs within a group recorded zero values for a response variable (commonly occurred in the MTci7-MPTL group), there was no information about lambs within the group; hence the corresponding group was removed before fitting the model to the data. The overall statistical significance of the group (or isolate) was assessed using the *F*-statistic for the LM, LMM and additive LMM or chi-square statistic for the GLMM. If the overall test for the group was statistically significant (*p *\<* *0.05), a set of biologically interesting contrasts to compare among groups was formulated, and two-sided probabilities for each contrast were obtained. Finally, these probabilities were adjusted using a False Discovery Rate (FDR) approach ([@bib0040]) to take into account multiple comparisons of means so that the expected proportion of false positives among all positives (i.e. rejecting the null hypothesis) was less than 5%. The FDR value, denoted in the results here as 'p~f~', therefore summarises the strength of evidence for there being a real difference in a way analogous to a standard p-value. For GLMMs, and LMs applied to transformed data, estimated means and confidence intervals are back transformed onto the original scale (i.e. count, proportion, AUC) and tabulated.

All statistical analyses were carried out using R software version 3.1.0 with appropriate R packages (stats, lme4, mgcv, multcomp, ggplot2) ([@bib0275]).

3. Results {#s0085}
==========

3.1. Parasite isolates {#s0090}
----------------------

Resistance was generated in all three previously susceptible isolates. Parasite survival at a dose rate of 2.5 mg/kg BW was achieved after 9, 12 and 13 rounds of selection for MTci5-13, MTci7-12 and MTci2-11 respectively (see Supplementary material).

3.2. Parasite establishment and worm burden {#s0095}
-------------------------------------------

Group had a statistically significant effect on the mean juvenile (p = 0.004), male (p \< 0.001) and total (p = 0.010), and weak evidence for female (p = 0.060) worm burdens in lambs. [Table 2](#t0015){ref-type="table"} presents the estimated means and 95% confidence limits of juvenile worms, males, females and total worm burdens for different isolates. Lambs from the MTci7 group showed significantly lower worm burdens on average: less males compared with MTci2 (p~f~ = 0.048), MTci5 (p~f~ \< 0.001) and MTci7-12-CON (p~f~ = 0.002); less females compared with MTci5 (p~f~ = 0.009) and less total worm burdens compared with MTci5 (p~f~ = 0.003) and MTci7-12-CON (p~f~ = 0.025).

Group had a statistically significant (p = 0.006) effect on the mean parasite establishment rate in lambs ([Table 2](#t0015){ref-type="table"}). Lambs in the MTci7 group showed the lowest mean establishment rate (0.22; 95% CI: 0.12, 0.38) whilst lambs in the MTci2-11-CON group showed the highest mean establishment rate (0.71; 95% CI: 0.54, 0.84). The MTci7 group showed a significantly lower mean establishment rate compared with MTci5 (p~f~ = 0.003) and MTci7-12-CON (p~f~ = 0.033). However, no evidence of differences in development rates of worms among groups was observed (p = 0.101).

3.3. Treatment efficacy {#s0100}
-----------------------

Treatment efficacies based on the percentage reduction in average estimated total worm burden between treated (-MPTL) and untreated (-CON) groups were 48%, 28% and 9% for MTci2-11, MTci7-12 and MTci5-13, respectively ([Table 2](#t0015){ref-type="table"}).

3.4. Adult worm body length {#s0105}
---------------------------

Average body length of adult female worms obtained from each of the groups measured between 8.6 mm and 9.7 mm in length ([Table 3](#t0020){ref-type="table"}). Average length of adult male worms ranged between 6.2 mm and 6.9 mm in length. However, there was no evidence that average worm body length differed between the groups (p = 0.242 and 0.193 for male and female, respectively).

3.5. Per capita fecundity {#s0110}
-------------------------

Average number of eggs *in utero* (EIU) for each of the groups ranged between 13 and 30 ([Table 3](#t0020){ref-type="table"}). The female worm length had a statistically significant effect (p \< 0.001) on mean EIU, and each mm increase in the female worm length resulted in a 30% increase of mean EIU. Group also had a statistically significant (p = 0.005) effect on the mean EIU. Results suggested that the mean EIU did not differ significantly (p~f~ \> 0.310) among the parental isolates, but the group MTci2-11-CON had significantly (p~f~ = 0.010) higher mean EIU (25, 95% confidence limits: 19, 33) than the MTci2-11-MPTL (13, 95% confidence limits: 10, 17). Results were similar when the estimates of EIU for different groups were adjusted for the female worm length.

3.6. Time to patency {#s0115}
--------------------

The time to patency, for this study, is defined as the time when a lamb produced a faecal egg count ≥ 25 eggs per gram. The estimated mean time to patency (lower, upper 95% confidence limits) were 19 (16, 22), 18 (15, 22) and 20 (18, 22) days post-infection for the parental isolates MTci2, MTci5 and MTci7, respectively; and 16 (14, 18), 19 (17, 21) and 15 (13, 18) days for the MPTL selected isolates MTci2-11, MTci5-13 and MTci7-12, respectively ([Table 3](#t0020){ref-type="table"}). The effect of group on the mean time to patency showed a weak evidence (p = 0.052). The mean time to patency among the parental isolates and among the selected isolates were not statistically significant (p~f~ \> 0.925). Although the mean time to patency shortened for two of the three selected isolates following selection, only MTci7-12 had significant (p~f~ = 0.048) shortening compared with its parental isolates MTci7.

3.7. Daily faecal egg count {#s0120}
---------------------------

[Figure 1](#f0015){ref-type="fig"} presents the observed FEC data as well as the mean FECs and corresponding 95% confidence limits for each of the groups over the time course of the study. The interaction effect of group and smooth term for day was statistically significant (p \< 0.001). Lambs of all groups started excreting eggs between days 14 and17 PI, and showed an increasing trend until the anthelmintic treatment on day 28 PI ([Figure 1](#f0015){ref-type="fig"}). Estimated mean faecal egg counts (95% lower, upper confidence limits) at day 28 PI for different isolates of parent and selected control lambs were: MTci2 (125; 95% confidence limits 57, 273); MTci2-11-CON (317; 136, 738); MTci5 (294; 142, 606); MTci5-13-CON (94; 42, 208); MTci7 (69; 31, 149) and MTci7-12-CON (499; 217, 1146) EPG. The mean egg count in the parental isolate MTci5 was higher than the parental isolate MTci7 on day 28 post infection, but the strength of evidence was weak (p~f~ = 0.057). At the same time point, the mean egg count in the selected isolate MTci7-12-CON was significantly (p~f~ = 0.006) higher compared with its corresponding parental isolate MTci7.

At post mortem examination (day 35 PI), the anthelmintic treatment efficacy based on the percentage reduction in FEC of treated versus untreated animals were 86%, 11% and 1% for MTci2-11, MTci7-12 and MTci5-13, respectively.

3.8. Cumulative faecal egg count {#s0125}
--------------------------------

[Figure 1](#f0015){ref-type="fig"} shows scatter plots of individual animals of each of the groups over the time course of the study. [Table 3](#t0020){ref-type="table"} presents the estimated mean cumulative faecal egg count for isolates of control parent and selected lambs and corresponding 95% lower and upper confidence limits for the different groups. Group had a statistically significant (p = 0.002) effect on the mean cumulative faecal egg counts in lambs. Among the parental isolates, the MTci7 had the lowest (1546; 95% CI: 337, 3635) and MTci5 had the highest (6898; 95% CI: 3855, 10820) estimated mean cumulative faecal egg counts, and these two parental isolates were significantly different (p~f~ = 0.040). Among the selected isolates, MTci5-13-CON had the lowest estimate (2949; 95% CI: 1111, 5665) and MTci7-12-CON had the highest estimate (10215; 95% CI: 6417, 14893) of cumulative faecal egg counts. The mean cumulative egg count in the selected isolate MTci7-12-CON was significantly higher compared with the parental isolate MTci7 (p~f~ = 0.002). Interestingly, MTci5-13-CON showed lower mean cumulative egg counts compared with its parental isolate (MTci5), although the difference was not statistically significant (p~f~ = 0.278).

4. Discussion {#s0130}
=============

Selection for monepantel resistance was "successful" in three discrete *T. circumcincta* isolates with different phenotypic sensitivities to "traditional" broad-spectrum anthelmintics. Selection was achieved after 9, 12 and 13 rounds of selection for MTci5-13, MTci7-12 and MTci2-11 respectively.

All selected parasite isolates were confirmed as MPTL resistant; the estimated resistance status of the selected isolates was confirmed with 48%, 28% and 9% reductions in worm burden at 7-days post Zolvix® administration for MTci2-11-MPTL, MTci5-13-MPTL and MTci7-12-MPTL, respectively, compared with untreated controls.

A selection process of administering increasing sub-therapeutic dosages to phenotyically characterised parental isolates was chosen for this work because it allowed the generation of a resistant population arising from a common ancestry which would allow future genotypic assessments. This process has been successfully used earlier to generate material to examine a number of candidate genes associated with benzimidazole ([@bib0035; @bib0205]) and macrocyclic lactone ([@bib0050; @bib0055; @bib0060; @bib0245]) resistance as well as to investigate non-specific mechanism of resistance ([@bib0240]). Very little work has been conducted on *T. circumcincta*, but previous reports of artificial selection for anthelmintic resistance appear to be longer in this species than in other species. Workers using similar procedures to select BZ ([@bib0175; @bib0095]) or ML ([@bib0120; @bib0110; @bib0290; @bib0280; @bib0085]) resistance in *Haemonchus contortus* generated it within 3 to 22 generations. [@bib0140] reported that selection pressures applied to a mixed population of nematode species selected for ivermectin resistance within four generations in *Trichostrongylus colubriformis* whilst *T. circumcincta* and *H. contortus* remained sensitive to the treatment in that time period. In *T. circumcincta*, morantel, levamisole and thiabendazole resistance was selected after around three years of selection pressure (no actual generations times stated; [@bib0190]). Potential reasons for these inter- and intra-species differences may reflect the isolates\' previous exposure to compounds of interest ([@bib0175]), inherent sensitivities to the compounds, e.g., dose limiting species ([@bib0345; @bib0010]); initial frequency of "potential" gene(s) for resistance within the population; dominance/recessive nature of inheritance; whether resistance is monogenic or polygenic or the impact of non-specific mechanisms of resistance on the ability of an isolate to survive the effects of an anthelmintic. The complexity of the situation means that changes in the phenotypes and genotypes of nematode populations as a result of anthelmintic usage is unlikely to be the same across the board.

The length of time to generate resistance is difficult to accurately calculate within this type of selection process, although a conservative estimate would suggest that resistance was selected within 9--13 generations, albeit the genes for resistance may have been selected sooner. In the field the first reported cases of MPTL resistance occurred two years after the launch of the Zolvix® in New Zealand, where treatment failure against *T. circumcincta* and *T. colubriformis* occurred after intense (17 separate occasions) dosing strategies ([@bib0195; @bib0310]).

Although the intensity of the selection process is significantly more rapid than that seen in the field, it is conceivable that re-infection of hosts predominantly with the progeny of worms that have survived anthelmintic treatment could occur. An example would be when the number of infective larvae in refugia, i.e. the parasite population that is unexposed to anthelmintic treatment that is available to be ingested by a host, is extremely low. This phenomenon has been shown to rapidly select for anthelmintic resistance in the field. Benzimidazole ([@bib0250]) and IVM ([@bib0045; @bib0335]) resistance is believed to have been selected when animals were treated around dry season and subsequently moved to "safe/clean" pasture ([@bib0065; @bib0220]). Rapid selection occurs because, even with only a small number of survivors, they form the only individuals available for re-infection of stock.

Because health programmes alter nematode mortality, they force the parasites to evolve or face extinction. One way that organisms do this is through changing their strategies/life history traits ([@bib0255; @bib0210]). In addition to differences in the time scale of the selection for resistance, it would be expected that phenotypes such as life history traits would be different within different isolates/populations and species. Differences in life history traits have been observed both following artificial and field selection of resistance to a number of different anthelmintic drug classes ([@bib0180; @bib0150; @bib0110; @bib0125; @bib0320; @bib0200; @bib0340]). Historically, it has been stated that interventions such as vaccination or chemotherapy, which potentially impact on the survival of the organism, would result in smaller, faster developing, less fecund worms ([@bib0235; @bib0270; @bib0210]). In situations where chances of survival are perceived to be high, the slower growing, larger and more fecund individuals would proliferate ([@bib0210]) even though larger size has been correlated with increased pathogenicity ([@bib0325]). It is believed that the environmental conditions, be that within or out with the host, under which a parasite develops can influence the phenotype of that organism. Changes in growth, fecundity or mortality, for example, can traditionally occur in two ways; phenotypic plasticity whereby an organism produces a number of progeny of different phenotypes under different conditions, or genotypic adaptation where there is a shift in genotype frequency to one that is better suited to new conditions ([@bib0330]). Phenotypic plasticity was believed to be the reserve of prokaryotic organisms such as bacteria, but work on trematodes has shown that even within parasite populations there is the capacity to accelerate development and reach precocious maturity sooner if conditions require ([@bib0265]).

Assessment of the life history traits of the MPTL selected isolates showed that in one of the cases (MTci7-12) statistically significant differences were observed in a number of the phenotypic traits assessed in relationship to survivability and propagation i.e. establishment rate, time to patency, per capita fecundity and overall egg output. Establishment has been suggested as the most important of the life history traits and also the one most difficult to compare experimentally ([@bib0070]). The findings from this current study suggested that the selected isolates had higher establishment rates compared with their derivatives with the exception MTci5-13. The findings are in general agreement with previous ones which showed that the establishment of resistant isolates were the same or higher than unselected isolates in resistant *H.* *contortus* ([@bib0180; @bib0150; @bib0110]) and *T.* *circumcincta* ([@bib0150; @bib0125]).

Overall net cumulative egg production and per capita fecundity increased in magnitude for MTci2-11 and MTci7-12 whilst a reduction was observed with MTci5-13 compared with corresponding parental isolates, although the increase was statistically significant only for the cumulative egg production in the MTci7-12 isolate. Taking into account the greater female burdens carried by these individual hosts, cumulative egg outputs were 3 to 7 times greater than the parental isolates. Previous studies reported similar findings in populations selected for IVM resistance ([@bib0180; @bib0340]) whilst others found only transient increases in egg excretion ([@bib0215]). As previously observed, the increase in egg numbers *in utero* was related to increase in the worm body length ([@bib0320; @bib0200]). In the current study, one mm increase in female body length resulted in 30% increase in eggs *in utero*.

In the early stages of resistance, particularly with the ML\'s, suppression in the generation and/or oviposition of eggs in adult female worms that survive treatment has been observed ([@bib0225; @bib0300; @bib0030]). The impact is believed to be due to temporary paralysing effects of the anthelmintics on uterine musculature ([@bib0305; @bib0230]). The result is the suppression in egg output in surviving worms whilst the drug is at a particular level which resumes when the drug concentration falls. [@bib0225] also suggested that dosing events may damage the worms so that although they survive, they will not contribute greatly to future populations. Analysis of historical faecal egg count data in conjunction with data from passage donors would suggest that the long term survivability of the selected isolates is no shorter than their parental counterparts, i.e. patency in donor animals used for propagation of isolates is similar irrespective of resistance status.

Although the work highlighted here would suggest that changes in life history traits may occur in response to anthelmintic selection, it must also be acknowledged that other factors may play roles. Phenotypic changes between the parental and/or selected isolates could (a) have occurred due to chance linkage events ([@bib0130; @bib0135]), with the life history trait being passed down to the progeny through the selection process, (b) be confounded by trial to trial effects and/or (c) through the passaging/culturing of the isolates for generations through lambs under laboratory conditions.

In conclusion, the study has established that MPTL resistance can be artificially selected in *T. circumcincta* in as short a time frame as nine generations. Selection for resistance impacted on the life history traits of the isolates, but the findings re-iterate the points stated earlier that it is difficult to predict what may occur to a parasite population following anthelmintic treatment.
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![The mean (line) faecal eggs counts (egg per gram, EPG) of lambs infected with either parental (MTci2, MTci5, MTci7) or monepantel selected (MTci2-11, MTci5-13, MTci7-12) isolates over the course of the study and corresponding 95% confidence limits (shaded region) estimated from the linear mixed model (LMM). Observed individual faecal egg counts are shown as closed circles. Groups in each panel represent parent isolates and selected isolates with (-MPTL) or without (-CON) monepantel treatment (on day 28 post-infection) i.e. MTci2, MTci5, MTci7, MTci7-MPTL, MTci2-11-CON, MTci2-11-MTPL, MTci5-13-CON, MTci5-13- MTPL, MTci7-12-CON, MTci7-12-MTPL.](ijpddr105-fig-0001){#f0015}

###### 

*Teladorsagia circumcincta* isolate designations pre- (parent) and post-selection for monepantel resistance.

  Parental designation   Anthelmintic sensitivity   Designation post monepantel selection   Designation during phenotypic characterisation   Original parental characterisation references                             
  ---------------------- -------------------------- --------------------------------------- ------------------------------------------------ ----------------------------------------------- ---------- -------------- ------------------------
  MTci2                  S                          S                                       S                                                S                                               MTci2-11   MTci2-11-CON   NA
  MTci2-11-MPTL                                                                                                                                                                                                        
  MTci5                  R                          R                                       R                                                S                                               MTci5-13   MTci5-13-CON   ([@bib0295; @bib0025])
  MTci5-13-MPTL                                                                                                                                                                                                        
  MTci7                  R                          R                                       R                                                R                                               MTci7-12   MTci7-12-CON   ([@bib0300; @bib0350])
  MTci7-12-MPTL                                                                                                                                                                                                        

BZ, fenbendazole; LV, levamisole; IV, ivermectin; MX, moxidectin; S, sensitive to anthelmintic class; R, resistant to anthelmintic class; NA, not available.

###### 

Mean (lower, upper 95% confidence limits) worm burdens of *Teladorsagia circumcincta* differentiated into male, female, juvenile and expressed as total worm counts as well as the establishment and development rates of worms estimated from GLMMs. The table also presents the percentage efficacy of anthelmintic treated groups of lambs relative to untreated control lambs seven days post-treatment. Percentage efficacy is estimated for selected lines only based on the worm burdens of treated lambs (i.e. MTci2-11-MPTL, MTci5-13-MPTL and MTci7-12-MPTL) relative to untreated control lambs (i.e. MTci2-11-CON, MTci5-13-CON and MTci7-12-CON).

  Isolate         Worm burden         Establishment rate[†](#tn0010){ref-type="table-fn"}   Development rate[\$](#tn0015){ref-type="table-fn"}   Percentage efficacy                                           
  --------------- ------------------- ----------------------------------------------------- ---------------------------------------------------- --------------------- ------------------- ------------------- ----
  MTci2           1275 (862, 1885)    1555 (1026, 2356)                                     85 (40, 179)                                         2937 (1990, 4335)     0.45 (0.28, 0.63)   0.97 (0.92, 0.99)   NA
  MTci5           1783 (1220, 2607)   2562 (1713, 3830)                                     19 (4, 81)                                           4395 (2996, 6447)     0.66 (0.48, 0.80)   1.00 (0.96, 1.00)   NA
  MTci7           560 (361, 868)      948 (612, 1468)                                       139 (75, 258)                                        1581 (1051, 2376)     0.22 (0.12, 0.38)   0.92 (0.83, 0.97)   NA
  MTci2-11-CON    2417 (1666, 3507)   2248 (1499, 3371)                                     0                                                    4675 (3189, 6854)     0.71 (0.54, 0.84)   1.00                NA
  MTci2-11-MPTL   1100 (740, 1635)    1306 (858, 1987)                                      9 (1, 73)                                            2444 (1651, 3617)     0.35 (0.21, 0.53)   1.00 (0.90, 1.00)   48
  MTci5-13-CON    974 (651, 1459)     1363 (896, 2074)                                      37 (13, 106)                                         2409 (1626, 3570)     0.36 (0.21, 0.54)   0.98 (0.92, 1.00)   NA
  MTci5-13-MPTL   910 (607, 1366)     1232 (807, 1880)                                      28 (8, 94)                                           2182 (1470, 3240)     0.32 (0.19, 0.50)   0.99 (0.92, 1.00)   9
  MTci7-12-CON    1654 (1129, 2424)   1900 (1262, 2861)                                     140 (76, 260)                                        3699 (2515, 5440)     0.57 (0.39, 0.74)   0.96 (0.91, 0.98)   NA
  MTci7-12-MPTL   1168 (785, 1737)    1467 (965, 2229)                                      56 (23, 136)                                         2654 (1792, 3929)     0.44 (0.28, 0.63)   0.98 (0.93, 1.00)   28

NA, Not applicable since the percentage efficacy is estimated for the selected lines only.

The establishment rate is defined as the proportion of juvenile and adult worms out of total infected worms (i.e. 7000).

The development rate is defined as the proportion of adult worms out of total worms established.

###### 

Summary of life history traits of *Teladorsagia circumcincta* isolates before and after selection for monepantel resistance. Values are means (lower, upper 95% confidence limits) estimated from GLMMs, LMMs and LMs.

  Isolate         Adult worm length (mm)   Eggs *in utero*   Eggs *in utero* per mm body length   Time to patency[†](#tn0020){ref-type="table-fn"} (days PI)   Total cumulative faecal egg count[\$](#tn0025){ref-type="table-fn"}   
  --------------- ------------------------ ----------------- ------------------------------------ ------------------------------------------------------------ --------------------------------------------------------------------- ---------------------
  MTci2           8.9 (8.3, 9.5)           6.5 (6.1, 6.9)    21 (16, 28)                          2.4 (1.9, 3.1)                                               19 (16, 22)                                                           2826 (1037, 5495)
  MTci5           9.5 (8.9, 10.2)          6.7 (6.3, 7.2)    28 (21, 37)                          3.0 (2.3, 3.8)                                               18 (15, 22)                                                           6898 (3855, 10820)
  MTci7           8.6 (7.9, 9.2)           6.2 (5.8, 6.6)    19 (14, 25)                          2.2 (1.7, 2.9)                                               20 (18, 22)                                                           1546 (337, 3635)
  MTci2-11-CON    9.7 (9.1, 10.3)          6.7 (6.3, 7.1)    25 (19, 33)                          2.6 (2.1, 3.3)                                               16 (14, 18)                                                           8067 (4741, 12273)
  MTci2-11-MPTL   9.6 (8.9, 10.2)          6.9 (6.5, 7.2)    13 (10, 17)                          1.4 (1.1, 1.8)                                               NA                                                                    NA
  MTci5-13-CON    9.0 (8.4, 9.7)           6.7 (6.3, 7.1)    18 (13, 24)                          2.0 (1.6, 2.6)                                               19 (17, 21)                                                           2949 (1111, 5665)
  MTci5-13-MPTL   9.0 (8.4, 9.6)           6.4 (6.1, 6.8)    23 (18, 31)                          2.6 (2.0, 3.3)                                               NA                                                                    NA
  MTci7-12-CON    9.7 (9, 10.3)            6.8 (6.4, 7.2)    28 (21, 37)                          2.9 (2.3, 3.7)                                               15 (13, 18)                                                           10215 (6417, 14893)
  MTci7-12-MPTL   9.4 (8.7, 10.0)          6.7 (6.2, 7.1)    30 (23, 40)                          3.3 (2.5, 4.2)                                               NA                                                                    NA

PI, post infection.

Time to patency was calculated as faecal egg count \>25 eggs per gram; data for selected lines combined, therefore no data quoted for monepantel (MPTL) treated groups (marked as NA, not applicable).

Estimated total faecal egg counts over the course of the trial; the outcomes for selected lines of monepantel (MPTL) treated groups were not estimated (marked as NA, not applicable).
